Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment… Read more
Agios Pharmaceuticals, Inc. (0HB0) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.069x
Based on the latest financial reports, Agios Pharmaceuticals, Inc. (0HB0) has a cash flow conversion efficiency ratio of -0.069x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-88.15 Million) by net assets ($1.28 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Agios Pharmaceuticals, Inc. - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Agios Pharmaceuticals, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Agios Pharmaceuticals, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agios Pharmaceuticals, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nanjing Yunhai Special Metals Co Ltd
SHE:002182
|
-0.014x |
|
REA Group Limited
PINK:RPGRY
|
0.175x |
|
RED CAT HDGS INC.DL -001
F:BQ73
|
N/A |
|
John Wiley & Sons B
NYSE:WLYB
|
0.011x |
|
Novavax Inc
NASDAQ:NVAX
|
0.309x |
|
Sejahteraraya Anugrahjaya Tbk
JK:SRAJ
|
0.025x |
|
NRW Holdings Ltd
AU:NWH
|
0.261x |
|
NAPCO Security Technologies Inc
NASDAQ:NSSC
|
0.072x |
Annual Cash Flow Conversion Efficiency for Agios Pharmaceuticals, Inc. (2012–2024)
The table below shows the annual cash flow conversion efficiency of Agios Pharmaceuticals, Inc. from 2012 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.54 Billion | $-389.84 Million | -0.253x | +30.70% |
| 2023-12-31 | $811.02 Million | $-296.06 Million | -0.365x | -29.85% |
| 2022-12-31 | $1.10 Billion | $-309.48 Million | -0.281x | +10.83% |
| 2021-12-31 | $1.29 Billion | $-407.32 Million | -0.315x | +56.68% |
| 2020-12-31 | $399.50 Million | $-290.76 Million | -0.728x | -25.78% |
| 2019-12-31 | $640.53 Million | $-370.62 Million | -0.579x | -30.68% |
| 2018-12-31 | $687.54 Million | $-304.42 Million | -0.443x | +41.71% |
| 2017-12-31 | $375.50 Million | $-285.23 Million | -0.760x | -806.36% |
| 2016-12-31 | $358.59 Million | $38.56 Million | 0.108x | +148.23% |
| 2015-12-31 | $345.12 Million | $-76.95 Million | -0.223x | -61.84% |
| 2014-12-31 | $430.81 Million | $-59.35 Million | -0.138x | +59.87% |
| 2013-12-31 | $164.28 Million | $-56.40 Million | -0.343x | +29.40% |
| 2012-12-31 | $101.89 Million | $-49.55 Million | -0.486x | -- |